NSE filing, NSE: ACCPL. Summary written from the filing by ALFA Finder's alert engine.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹190.05
- Market cap
- ₹211.3 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 21.9×Sector 45.9×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Results Update
Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.
Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY
Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.
- Key figure
- Net profit ₹8.2 Cr · +70.8% YoY
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Other financial results announcements
All →Confidence Futuristic Energetech Q2 FY27 Results: Net Profit ₹1.2 Cr, Up 500.0% YoY
Confidence Futuristic Energetech Ltd reported revenue from operations of ₹41.7 Cr (+66.8% YoY) and net profit of ₹1.2 Cr (+500.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.2 Cr · +500.0% YoY
Priority Jewels Q2 FY27 Results: Net Profit ₹6.5 Cr, Up 22.6% YoY
Priority Jewels Ltd reported revenue from operations of ₹183.5 Cr (+16.5% YoY) and net profit of ₹6.5 Cr (+22.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹6.5 Cr · +22.6% YoY
Integra Essentia Q2 FY27 Results: Net Profit ₹0 Cr
Integra Essentia Ltd reported revenue from operations of ₹142 Cr (+17.6% YoY) and net profit of ₹0 Cr for Q2 FY27.
- Key figure
- Net profit ₹0 Cr
Mercury Ev-Tech Q2 FY27 Results: Net Profit ₹1.2 Cr, Down 33.3% YoY
Mercury Ev-Tech Ltd reported revenue from operations of ₹30.1 Cr (-11.5% YoY) and net profit of ₹1.2 Cr (-33.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.2 Cr · -33.3% YoY
Jay Jalaram Technologies H1 FY27 Results: Net Profit ₹9.3 Cr, Up 78.8% YoY
Jay Jalaram Technologies Ltd reported revenue from operations of ₹655.8 Cr (+83.7% YoY) and net profit of ₹9.3 Cr (+78.8% YoY) for H1 FY27.
- Key figure
- Net profit ₹9.3 Cr · +78.8% YoY
Latent View Analytics Q2 FY27 Results: Net Profit ₹48.5 Cr, Up 6.1% YoY
Latent View Analytics Ltd reported revenue from operations of ₹294.1 Cr (+14.2% YoY) and net profit of ₹48.5 Cr (+6.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹48.5 Cr · +6.1% YoY